Quince Therapeutics, Inc. (QNCX)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
17.25 USD
-0.29
(-1.653%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:24 a.m. EDT
The investment case for Quince Therapeutics is currently broken by a combination of existential corporate risk and deteriorating fundamentals. The company is navigating a perilous period of strategic uncertainty, with headlines confirming plans for a reverse merger and explicit bankruptcy risks, which has triggered a severe sell-off. Financially, the picture is stark: the stock has lost over 95% of its value over the past six years, trading at a negative forward P/E with significant losses in free cash flow and equity. While the recent Phase 2a data for LAM-001 offers a glimmer of scientific hope, the market is pricing in the high probability of a distressed liquidation or a chaotic restructuring rather than a clean turnaround. The options market confirms this pessimism, with heavy put buying suggesting traders expect further declines. Until the corporate structure stabilizes and the path to profitability becomes clear, this remains a speculative gamble on survival rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.065282 |
| MSTL_90 | 0.080003 |
| AutoTheta | 0.137610 |
| MSTL | 0.144887 |
| AutoETS | 0.168124 |
| MSTL_66 | 0.234340 |
| MSTL_66_90 | 0.439553 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 0.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.143 |
| Excess Kurtosis | -1.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.591 |
| Market Cap | 16,869,862 |
| Forward P/E | -3.27 |
| Beta | 1.40 |
| Previous Name | Cortexyme, Inc. |
| Website | https://quincetx.com |
As of July 11, 2026, 4:24 a.m. EDT: Speculators are positioning aggressively for a massive crash rather than a rally. Call volume is negligible and concentrated at strikes far below the current price ($0.50-$2.00), while put volume is active at the money and slightly out-of-the-money. This indicates a 'bear put spread' or hedging strategy where traders are betting on further downside or protecting existing long positions against a collapse, rather than anticipating a recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9507303 |
| Address1 | 611 Gateway Boulevard |
| Address2 | Suite 273 |
| All Time High | 24,396.0 |
| All Time Low | 15.1 |
| Ask | 22.27 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 38,355 |
| Average Daily Volume3 Month | 67,338 |
| Average Volume | 67,338 |
| Average Volume10Days | 38,355 |
| Beta | 1.401 |
| Bid | 12.83 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.136 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 17.25 |
| Current Ratio | 2.917 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 18.2 |
| Day Low | 17.21 |
| Debt To Equity | 2.591 |
| Display Name | Quince Therapeutics |
| Earnings Timestamp End | 1,786,478,400 |
| Earnings Timestamp Start | 1,786,478,400 |
| Ebitda | -48,461,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.076 |
| Enterprise Value | -3,697,611 |
| Eps Current Year | -1.48 |
| Eps Forward | -5.28 |
| Eps Trailing Twelve Months | -210.0 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 21.0122 |
| Fifty Day Average Change | -3.7621994 |
| Fifty Day Average Change Percent | -0.17904834 |
| Fifty Two Week Change Percent | -95.07303 |
| Fifty Two Week High | 910.0 |
| Fifty Two Week High Change | -892.75 |
| Fifty Two Week High Change Percent | -0.98104393 |
| Fifty Two Week Low | 15.1 |
| Fifty Two Week Low Change | 2.1499996 |
| Fifty Two Week Low Change Percent | 0.14238408 |
| Fifty Two Week Range | 15.1 - 910.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,557,408,600,000 |
| Float Shares | 731,871 |
| Forward Eps | -5.28 |
| Forward P E | -3.2670453 |
| Free Cashflow | -30,789,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 38 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00316 |
| Held Percent Institutions | 0.14206 |
| Implied Shares Outstanding | 977,963 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,782,777,600 |
| Last Split Factor | 1:20 |
| Long Business Summary | Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California. |
| Long Name | Quince Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 16,869,862 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_266230063 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -36,155,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 16,869,861 |
| Number Of Analyst Opinions | 3 |
| Open | 17.59 |
| Operating Cashflow | -39,451,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 415 910 5717 |
| Pre Market Change | -0.13999939 |
| Pre Market Change Percent | -0.8115907 |
| Pre Market Price | 17.11 |
| Pre Market Time | 1,784,016,473 |
| Prev Name | Cortexyme, Inc. |
| Previous Close | 17.54 |
| Price Eps Current Year | -11.655405 |
| Price Hint | 2 |
| Price To Book | 15.184858 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.819 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.290001 |
| Regular Market Change Percent | -1.65337 |
| Regular Market Day High | 18.2 |
| Regular Market Day Low | 17.21 |
| Regular Market Day Range | 17.21 - 18.2 |
| Regular Market Open | 17.59 |
| Regular Market Previous Close | 17.54 |
| Regular Market Price | 17.25 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 52,600 |
| Return On Assets | -0.45439997 |
| Return On Equity | -1.9289999 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 977,963 |
| Shares Percent Shares Out | 0.1153 |
| Shares Short | 112,788 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 102,989 |
| Short Name | Quince Therapeutics, Inc. |
| Short Percent Of Float | 0.1157 |
| Short Ratio | 4.14 |
| Source Interval | 15 |
| State | CA |
| Symbol | QNCX |
| Target High Price | 100.0 |
| Target Low Price | 70.0 |
| Target Mean Price | 83.33333 |
| Target Median Price | 80.0 |
| Total Cash | 18,163,000 |
| Total Cash Per Share | 22.285 |
| Total Debt | 406,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -210.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 239.68304 |
| Two Hundred Day Average Change | -222.43304 |
| Two Hundred Day Average Change Percent | -0.92802995 |
| Type Disp | Equity |
| Volume | 52,600 |
| Website | https://quincetx.com |
| Zip | 94,080 |